New Center of Excellence targets reducing disparities in cancer care and outcomes 06/15/2009 (University of South Florida Health) A new Center of Excellence at the University of South Florida and Moffitt Cancer Center will focus on research, education and training, and community outreach to reduce cancer health disparities among minority and underserved populations. The joint program is funded by a $6 million grant from the National Institutes of Health. Colleges, communities combat off-campus student drinking 06/15/2009 (Journal of Studies on Alcohol and Drugs) Programs that bring colleges and their surrounding neighborhoods together may help reduce off-campus drinking problems, a new study suggests. College drinking problems, deaths on the rise 06/15/2009 (Journal of Studies on Alcohol and Drugs) Alcohol-related deaths, heavy drinking episodes and drunk driving have all been on the rise on college campuses over the past decade, a new government study shows. Dangerous college drinking: Prevention is possible, studies suggest 06/15/2009 (Journal of Studies on Alcohol and Drugs) Alcohol is sometimes seen as part and parcel of college life, but there are programs that can significantly reduce students' risky drinking, according to a series of studies in a special college drinking supplement of the Journal of Studies on Alcohol and Drugs. Huntington's disease deciphered 06/14/2009 (University of Illinois at Chicago) Researchers at the University of Illinois at Chicago College of Medicine have discovered how the mutated Huntington gene acts on the nervous system to create the devastation of Huntington's disease. NIAID media availability: New strategy proposed for designing antibody-based HIV vaccine 06/14/2009 (NIH/National Institute of Allergy and Infectious Diseases) Most vaccines that protect against viruses generate infection-fighting proteins called antibodies that either block infection or help eliminate the virus before it can cause disease. Attempts to create a vaccine that induces antibodies that prevent HIV infection or disease, however, have so far been unsuccessful. But several recent studies suggest promising new research directions for the development of an antibody-based HIV vaccine. Aussie and Kiwi researchers make double MS genetic discovery 06/14/2009 (University of Melbourne) Australian and New Zealand researchers have accelerated research into Multiple Sclerosis by discovering two new locations of genes which will help to unravel the causes of MS and other autoimmune disease. Their findings will be published today in the prestigious journal Nature Genetics. UNC study suggests new approach to common cause of blindness 06/14/2009 (University of North Carolina School of Medicine) Researchers at the University of North Carolina at Chapel Hill School of Medicine in collaboration with lead investigators at the University of Kentucky have identified a new target for the diagnosis and treatment of age-related macular degeneration, the most common cause of blindness in older Americans. NYU Langone Medical Center researchers identify key gene in deadly inflammatory breast cancer 06/14/2009 (NYU Langone Medical Center / New York University School of Medicine) Aggressive, deadly and often misdiagnosed, inflammatory breast cancer is the most lethal form of primary breast cancer, often striking women in their prime and causing death within 18 to 24 months. Now, scientists from the Cancer Institute at NYU Langone Medical Center have identified a key gene -- eIF4G1 -- that is overexpressed in the majority of cases of IBC, allowing cells to form highly mobile clusters that are responsible for the rapid metastasis that makes IBC such an effective killer. Good news and bad for dad this Father's Day 06/14/2009 (University of Utah Health Sciences) It was long believed that conception does not involve equals. The egg is a relatively large biological factory compared with the tiny sperm, which delivers to the egg one copy of the father's genes. However, a new study from Huntsman Cancer Institute at the University of Utah reveals that the father's sperm delivers much more complex genetic material than previously thought. The findings could lead to a test to help couples deal with infertility. Individuals who apply pesticides are found to have double the risk of blood disorder 06/12/2009 (American Society of Hematology) A study involving 678 individuals who apply pesticides, culled from a US Agricultural Health Study of over 50,000 farmers, recently found that exposure to certain pesticides doubles one's risk of developing an abnormal blood condition called MGUS (monoclonal gammopathy of undetermined significance) compared with individuals in the general population. New study reveals structure of the HIV protein shell 06/12/2009 (Scripps Research Institute) New research by scientists at the Scripps Research Institute and other institutions provides a close-up look at the cone-shaped shell that is the hallmark of human immunodeficiency virus, revealing how it is held together -- and possible ways to break it apart. Hear! Hear! Texas wines fight cancer growth 06/12/2009 (Texas A&M AgriLife Communications) It's happy hour for Texas wineries. Research now shows that wines produced in the Lone Star State share the anti-cancer traits known to exist in wines from other producing regions.Extracts from two Texas red wines decreased cancer cell growth in a comparable magnitude as other wines previously studied, according to Texas AgriLife Research. Appetite-stimulating hormone is first potential medical treatment for frailty in older women 06/12/2009 (University of Pennsylvania School of Medicine) Older women suffering from clinical frailty stand to benefit from the first potential medical treatment for the condition, according to a study presented today by Penn Medicine researchers at ENDO. Ghrelin, a hormone that stimulates appetite, was administered to older women diagnosed with frailty, a common geriatric syndrome characterized by unintentional weight loss, weakness, exhaustion and low levels of anabolic hormones which increases risk of falls, hospitalizations, disability and death. IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 06/12/2009 (European League Against Rheumatism) After five years of receiving infliximab (IFX) anti-TNF therapy, 61.8 percent of patients with ankylosing spondylitis (AS) showed substantial clinicalbenefit and 27.6 percent achieved ASAS partial remission. At five years, 78.4 percent of AS patients had no arthritis and 84.9 percent had no enthesitis. Patients continued to show a sustained high response rate, low disease activity, good functional state and low c-reactive protein levels, according to study results presented at EULAR 2009. Over half of people with rheumatoid arthritis have periodontitis 06/12/2009 (European League Against Rheumatism) Over half (56 percent) of people with RA also have periodontitis, displaying fewer teeth than healthy matched controls, high prevalence of oral sites presenting dental plaque and advanced attachment loss (the extent of periodontal support that has been destroyed around a tooth), according to the results of a new study presented today at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. RA individuals from lower GDP countries keep working despite worse symptoms than richer countries 06/12/2009 (European League Against Rheumatism) Individuals diagnosed with rheumatoid arthritis (RA) in lower gross domestic product (GDP) countries are more likely to continue working despite higher disease activity and functional disability scores compared to their counterparts in higher GDP countries according to a new multinational study presented today at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. Universitat Autonoma de Barcelona researchers first to clone mice in Spain 06/12/2009 (Universitat Autonoma de Barcelona) Universitat Autònoma de Barcelona researchers are the first to have cloned mice in Spain. Cloe, Cleo and Clona are three female brown-colored mice and were born respectively on May 12, June 3 and June 10. The cloning of mice is part of a research being carried out to study new ways to improve the efficiency of the cloning process. 3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 06/12/2009 (European League Against Rheumatism) Three new studies have individually shown the anti-TNF (tumor necrosis factor) therapy etanercept to be effective, with a good safety profile, in children under four years of age with JIA, and associated with improved health-related quality of life in a substantial proportion of children with JIA. The data are being presented at the Pediatric Rheumatology European Society Congress 2009, a joint congress with EULAR in Copenhagen, Denmark. Better access to info and dialogue with HCPs on sexual issues for rheumatology patients 06/12/2009 (European League Against Rheumatism) Patients with rheumatic diseases want more information and better communication with health-care professionals on the sexual issues related to their conditions, according to the results of a new study presented today at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. Early treatment of systemic onset JIA with anakinra restores the IL-18 response 06/12/2009 (European League Against Rheumatism) First-line treatment with anakinra (an interleukin-1 receptor antagonist), results in a "good" clinical response in patients newly diagnosed with systemic onset juvenile idiopathic arthritis, and restores the deficient IL-18 response of natural killer cells, according to a new study presented today at PReS 2009, a joint congress with the 2009 Congress of the European League Against Rheumatism in Copenhagen, Denmark. Winter- and spring-onset RA patients have worse 6 month outcomes than those with summer onset 06/12/2009 (European League Against Rheumatism) When a patient's first symptoms of RA occur in winter, severity of RA (as measured by the modified Total Sharp Score, mTSS, assessment of erosion and joint space narrowing) was rated more severe at six months, compared to patients whose RA first became symptomatic in summer. Patients with first symptoms in spring showed poorer radiographic outcome compared to summer-onset patients. Majority won't have access to antivirals in pandemic but generic drugs could help prevent deaths 06/12/2009 (Wiley-Blackwell) Eighty-eight percent of the world's population won't have timely access to affordable supplies of vaccines and antivirals in the current flu pandemic. But it is possible that inexpensive generic drugs that are readily available -- even in developing countries -- for conditions like diabetes and high cholesterol, could save millions of lives. Flu experts have also warned that bird flu cases are continuing to rise and it is essential that health professionals also continue to monitor that situation very carefully. Anxiety and depression lower quality of life in majority of systemic lupus erythematosus patients 06/12/2009 (European League Against Rheumatism) Ninety-three percent of patients with systemic lupus erythematosus suffer anxiety and depression which significantly affects both their physical and emotional quality of life (QoL), according to the results of a new study presented today at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. Logistic regression analysis revealed that depression was the most significant factor shown to affect QoL. 63 percent of RA patients suffer psychiatric disorders, with depressive spectrum conditions most likely 06/12/2009 (European League Against Rheumatism) Over half (63 percent) of patients with rheumatoid arthritis (RA) also suffer from psychiatric disorders, with the majority of these (87 percent) occurring in the depressive spectrum, according to the results of a new study presented today at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. Interestingly, over half (52 percent) of the patients studied indicated that they had experienced stress events before the onset of their RA. This page contains recent news articles, when available, and an overview of the following medications: Abatacept | Abilify | Accupril | Accupril | Accutane | Aceon | Aciphex | Aciphex | Actonel | Actonel | Actos | Actos | AcuTect | AcuTect | Adderall | Adderall | Advair Diskus | Advair Diskus | Agenerase | Agenerase | Aggrastat | Aggrastat | Alamast | Alamast | Alemtuzumab | Aleve | Aleve | Alimta | Alimta | Alinia | Alinia | Almotriptan malate | Aloxi | Aloxi | Alrex | Alrex | Altace | Amerge | Amiodarone | Amitiza | Amnesteem | Amphadase | Anaprox | Angiomax | Angiomax | Anidulafungin | Antagon | Antagon | Anthelios SX | Anthelios SX | Anthelios SX | Anthelios SX | Apidra | Apidra | Apokyn | Apokyn | Aprepitant | Aprotinin | Aptivus | Aranesp | Arava | Arava | Argatroban | Aripiprazole | Arixtra | Arixtra | Aromasin | Arranon | Arranon | Aspirin | Atacand | Atazanavir sulfate | Avandia | Avastin | Avelox | Avobenzone, Ecamsule, Octocrylene | Avodart | Avodart | Axert | Azilect | Azopt | Azopt Baraclude | Benazepril | Benicar | Benicar | Bevacizumab | Bextra | Biaxin | Bimatoprost | Boniva | Boniva | Bortezomib | Bupropion | Byetta a b | c d | e f | h g i j | k l | m n | o p q r | s t | u v w x y z |